Oestrogen and progesterone receptor analyses are used-widely in the selection of patients with advanced breast cancer for endocrine treatment. It has been established that 50-60% of patients whose tumours contain cytosol oestrogen receptors (RE,) at the time of treatment will respond to endocrine manoeuvres, and that only -10% of patients will respond when REr is absent (Barnes et al., 1979; McGuire, 1980; King, 1980) . The proportion of patients likely to respond is higher when progesterone receptor (RPC) is also present (Barnes et al., 1979; McGuire, 1980; King, 1980 
Oestrogen and progesterone receptor analyses are used-widely in the selection of patients with advanced breast cancer for endocrine treatment. It has been established that 50-60% of patients whose tumours contain cytosol oestrogen receptors (RE,) at the time of treatment will respond to endocrine manoeuvres, and that only -10% of patients will respond when REr is absent (Barnes et al., 1979; McGuire, 1980; King, 1980) . The proportion of patients likely to respond is higher when progesterone receptor (RPC) is also present (Barnes et al., 1979; McGuire, 1980; King, 1980 . Many metastases are not readily accessible for biopsy and treatment is often decided on the basis of receptor studies assessed in the primary tumours or lymph nodes before dissemination is apparent. The extent to which receptor status may vary with time is unknown, but may be of considerable importance when the choice of systemic treatments is being considered.
In this report we describe our experience of receptor analyses in patients who have had more than one lesion submitted for assay. (Barnes et al., 1979 Patients were excluded if they had taken tamoxifen in the month preceding their biopsy. Apart from this, 20 patients had some form of hormone treatment in the interval between biopsies. Seven had tamoxifen, 6 ovarian ablation, stilboestrol, 1 norethisterone, and 5 had a combination of some of these, in sequence. In one other, the natural menopause occurred between biopsies.
Materials and methods

Specimens
Eleven of the patients who had asynchronous biopsies were pre-menopausal, and 66 were postmenopausal at the time of both biopsies.
Patients with technically unsatisfactory assays e.g. negative results with low cytosol protein concentrations were also excluded. Three patients who had cutaneous lesions removed for receptor assay but not sent for histological confirmation of the clinical diagnosis of malignancy have been included. In all other patients malignancy was confirmed by histological examination.
Results
Synchronous biopsies
The assays disagreed on the presence or absence of RE, and RPC and on the combinations of REr and RP, (Double receptor status) in 11, 13 and 16% of biopsies respectively (Table I) .
Asynchronous biopsies RE, status varied in 23% of the paired assays.
Although higher, this proportion was not significantly different from that found in synchronous biopsies (Table I ). The extent of variation was similar whether the initial lesion contained receptor or not (Table II) . RP, status differed in 30% of the asynchronous samples.
When the first lesion contained RPc, 49% of patients did not have RPc in a later biopsy. When the first lesion did not contain RPC, it was found in 16% of the subsequent samples (Table II) . When both receptors were considered together 43% of asynchronous biopsies did not maintain the same classification.
Five patients in whom there was RPC activity in one biopsy had evidence of RPC activity below the found in the first biopsy differed in a later receptor analysis. The differences in the extent of variation between the groups were not significant (Table III) .
Exclusion of the patients who had had some form of hormone treatment in the interval between biopsies did not reduce the proprtion of cases in which some variation occurred (Table IV) .
Thirteen of the 26 patients (50%) in whom the interval between the biopsies was <1 year had The mean concentration of RE, in those patients who were RE, -ve initially but in whom RE, was found in later biopsy was 22fmolmg-' (range 6-59fmolmg-'). When RP, was found only in the later biopsy the mean concentration was 41 fmol mg-' (range 17-144 fmol mg-1).
Discussion
The proportion of patients in whom the ER, status was consistent is similar to that quoted in other reports which give a range of 66-85% agreement between biopsies (Brennan et al., 1979 . Webster et al., 1978 . Rosen et al., 1977 .
Less data are available on the variation of RP, between sites and with time, but other workers have noted a similar inconsistency (Koenders et al., 1980 . Matsumoto et al., 1978 . In this study loss of progesterone receptor was particularly common. In only one patient could this have been due to the menopause occurring in the interval between the biopsies.
Previous reports have not considered the changes which may take place in the combined receptor status. Our finding of a change in 43% of asynchronous biopsies casts serious doubt on the value of classifying patients at an early stage in their disease.
Several reports have been published on the response to endocrine treatment in relation to receptor status which fail to distinguish between contemporary or past receptor estimations . MacFarlane et al., 1980 . Mosely et al., 1980 . It is essential to distinguish between contemporary and previous data when reporting response in relation to receptor status.
Some authors have suggested that a response is more likely with high concentrations of RE, than with low ones and that the measurement of PRC may be unnecessary . Osborne et al., 1980 . Paridaens et al., 1980 (Campbell et al., 1981) . The receptor status of secondary deposits at these sites may be easier to predict and information on receptor status at these sites in relation to previous biopsies would be of interest.
The clinical significance of this variation in receptor status with time will only be known when there are enough patients who have had reliable estimations both well before and at the time of endocrine treatment and for whom the response to treatment is known. Until then it seems prudent, when possible, to take biopsies for receptor estimations at the time when systemic treatment is proposed rather than to rely upon assays performed at the time of mastectomy or of a previous recurrence.
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